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ABSTRACT
A new preservative-free fixed-dose combination
of 0.0015% tafluprost, a prostaglandin F2a
analog, and 0.5% timolol (TAF/TIM; Santen
Oy, Tampere, Finland), a beta-adrenergic
antagonist has recently been developed. The
intraocular pressure (IOP) reduction with TAF/
TIM in open-angle glaucoma and ocular
hypertension is similar to that of other
prostaglandin–timolol fixed-combination
products. Patients with high IOP responded
well to TAF/TIM with reductions of up to 40%
([13 mmHg) and beyond. Compared to
previous controlled and double-masked
clinical trials with DuoTrav (Alcon, Fort
Worth, USA) and Ganfort (Allergan, Irvine,
USA), TAF/TIM caused less superficial ocular
side effects and less conjunctival hyperemia.
Plausible explanations for the differences in side
effects between the fixed-combination products
are discussed.
Keywords: DuoTrav; Fixed-dose combination;
Ganfort; Hyperemia; Intraocular pressure;
Ophthalmology; Preservative free; Side effects;
Tafluprost; Timolol; Xalacom
INTRODUCTION
A new preservative-free fixed-dose combination
product consisting of 0.0015% tafluprost and
0.5% timolol [TAF/TIM, Santen Oy, Tampere,
Finland; Marketing authorization pending at
time of manuscript preparation. For the other
reviewed products proprietary names Xalacom
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(Pfizer, New York, USA), DuoTrav (Alcon, Fort
Worth, USA), and Ganfort (Allergan, Irvine,
USA) are used, to distinguish from studies with
possible generic preparations] has recently been
developed for the treatment of open-angle
glaucoma and ocular hypertension. The
purpose of the present paper is to review TAF/
TIM along with the other prostaglandin–
timolol fixed-combination products on the
market—Xalacom (0.005% latanoprost and
0.5% timolol), DuoTrav (0.004% travoprost
and 0.5% timolol), and Ganfort (0.03%
bimatoprost and 0.5% timolol)—based on the
double-masked, controlled phase III clinical
trials that have been published. The
intraocular pressure (IOP)-reducing effects of
the products are discussed and the side effect
profiles are summed up based on the receptor
pharmacology of the compounds and the
presence or absence of preservatives.
The pharmacological profiles of latanoprost,
travoprost, and bimatoprost have been
presented and discussed in detail [1–3]. All
these compounds are prodrugs of synthetic
analogs of prostaglandin F2a (PGF2a) and act
on prostaglandin F (FP) prostanoid receptors.
Bimatoprost, an ethylamide of 17-phenyl,
18,19,20-trinor-PGF2a can be regarded both as
a prostaglandin prodrug and a prostamide [4–6].
Specific prostamide receptors, like the
prostanoid receptors, have not been identified
so far. However, heterodimerization of
prostanoid receptors may act as binding/
signaling site for the prostamide [7].
Similar to the other prostaglandin analogs,
tafluprost (15-difluoro-16-phenoxy-
17,18,19,20-tetranor-PGF2a-isopropyl ester) is a
prodrug. The free acid of tafluprost is an FP
prostanoid receptor agonist with some spillover
of activity on the prostaglandin E receptor 3
(EP3) [8, 9]. Tafluprost-free acid appears to be
the most potent of the prostaglandin analogs
used for glaucoma treatment with a half
maximal effective concentration (EC50) value
at the FP receptor of around 5 9 10-10 mol/L.
Tafluprost is a unique prostaglandin analog in
the sense that the hydrogen and hydroxyl
group at carbon 15 have been replaced by two
fluorine atoms; this affects both the
pharmacology and metabolism of the drug.
Timolol is a well-known unselective beta-
adrenergic antagonist that has been widely used
for glaucoma treatment since the late 1970s.
Many review articles have been published on
the pharmacology and use of timolol in
glaucoma treatment [10–12]. The first fixed-
combination product of a prostaglandin with
timolol was Xalacom, followed by DuoTrav
and Ganfort.
Already the first phase III clinical trials with
Xalacom showed that the additional effect of
combining timolol with latanoprost compared
to latanoprost or timolol alone was somewhat
smaller than expected [13, 14]. The same
finding has been reported for all the
prostaglandin–timolol fixed-combination
products: DuoTrav [15, 16], Ganfort [17–19],
and TAF/TIM [20]. Clearly, from a dose regimen
point of view, the two drugs are difficult to
combine into one and get a full additive effect.
The prostaglandin/prostamide should optimally
be administered once daily in the evening to get
the peak effect during the morning hours when
IOP is physiologically at its highest. Timolol, in
turn, is usually administered twice daily. To a
certain extent, the worse-than-expected efficacy
of the fixed-combination products is due to the
design of previous regulatory trials (morning-
dosed combination products were compared to
evening-dosed prostaglandins, therefore,
daytime measurements tended to
underestimate the relative efficacy of
combination products). Additional issues
included the selection of suboptimal baseline
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pressure and the inclusion of patients who were
well controlled on monotherapy or were
timolol non-responders. Despite these
challenges, additional IOP reduction is
achieved with the combination products in
comparison with the monotherapies. This
could be particularly relevant for patients who
suffer from high IOP. Treatment compliance is
another beneficial aspect that can be
anticipated to improve with the combination
products administered once daily [21–24].
METHODS
The present paper is based on a review of the
double-masked, controlled clinical trials with
the four fixed-combination products that have
published results in the ophthalmic literature:
Xalacom, DuoTrav, Ganfort, and TAF/TIM.
The paper focuses entirely on the data reported
with these combination products; study results
obtained with the control substances have not
been included. Specifically, interest was laid in
determining the relationship between the
baseline IOP and treatment-induced change in
IOP. A PubMed search with keywords
latanoprost, travoprost, or bimatoprost, combined
with timolol fixed was carried out in early July
2014. A prerequisite for accepting a trial in our
paper was the washout of previous IOP-reducing
medication before the initiation of the
treatment with the combination product.
Thus, studies with crossover design or an
active run-in phase before the treatment
period were not included in the evaluation of
the IOP-reducing effect. For example, some
Xalacom studies [13, 14, 25, 26] fell into this
category. In addition, studies with an
exclusively Asian population were excluded
[27]. Open-label or investigator-masked
(single-masked) studies were not included due
to the potential problem with bias. Other
factors that needed consideration were the
length of the treatment that varied among the
studies and the type of endpoint. Owing to
these, we focused on the analysis of mean IOP
change at 3 months; this standardized the
follow-up period to that applied in majority of
the studies and provided a distinct study
endpoint (Table 1; 10 studies). The robustness
of these primary results was then assessed
including all selected studies in the analysis
(Table 1; 16 studies). It should be noted that the
reductions of IOP (in mmHg) were generally
calculated from the mean values given in the
publications, because the underlying raw data
were available only for the two TAF/TIM studies.
Thus, these figures represent fair
approximations rather than exact values.
Statistical analyses were conducted using SAS
System for Windows, version 9.3 (SAS Institute
Inc., Cary, NC, USA).
Regarding safety, the emphasis was on
investigating hyperemia and ocular irritation
(or discomfort), which are the most frequent
side effects with prostaglandins [28]. Increased
iris pigmentation, hyperpigmentation of the
skin, and growth of eyelashes have not been
dealt with as the duration of the treatment was
only 3 months or less in most of the studies
(Table 2; 11 out of 16 studies). Incidences of the
side effects—expressed as percentages—were
obtained by summing up the counts of the
individual side effects within a specific category.
For example, subjective symptoms of various
forms of discomfort (burning, stinging, itching,
pruritus, foreign body sensation, ocular pain,
ocular discomfort, and dry eye sensation) were
lumped together and described as ocular
‘‘irritation’’. In most papers, drug-related
adverse events have been incorporated into
tables or are mentioned in the text only if
their occurrence exceeded 2%. Thus, drug-
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related adverse events that occurred at a lower
incidence than 2% were generally not included.
Again, it is stressed that our figures represent
only approximations, since we had limited
access to the raw data. Also, the evaluation of
hyperemia has varied among the studies, but
this shortcoming is at least partly compensated
by the fact that all studies were double masked
and had a control substance.
The analysis in this article is based on
previously conducted studies and does not
involve any new studies of human or animal
subjects performed by any of the authors.
RESULTS
Intraocular Pressure
The primary results—that is, mean IOP changes
at 3 months versus mean baseline IOP—for the
fixed prostaglandin–timolol combination
products are presented as a scatter plot in
Table 1 Different ﬁxed-combination prostaglandin–timolol drugs in double-blind, controlled, phase III clinical trials based
on the literature (excluding studies using crossover design, run-in drug, or direct switch from previous medication)
Drug Number of
patients
Endpoint Dataset Dosing time of
ﬁxed combination
References
Xalacom 255 3 months ITT Evening Diestelhorst and Larsson [39]
Xalacom 164 12 monthsa PP Morning Topouzis et al. [40]
Xalacom 129 3 months ITT Evening Higginbotham et al. [32]
Xalacom 170 3 months ITT Evening Palmberg et al. [41]
DuoTrav 151 3 months PP Morning Hughes et al. [29]
DuoTrav 155 3 months PP Morning Schuman et al. [15]
DuoTrav 82 3 months ITT Morning Barnebey et al. [16]
DuoTrav 168 12 monthsa PP Morning Topouzis et al. [40]
DuoTrav 154 6 weeksa ITT Morning Teus et al. [42]
DuoTrav 372 6 weeks PP Morning Kitazawa et al. [43]
Ganfort 178 3 weeks ITT Morning Hommer et al. [17]
Ganfort 533 3 months ITT Morning Brandt et al. [18]
Ganfort 533b 12 monthsb ITT Morning Lewis et al. [19]
Ganfort 516c 3 months PP Morning Goldberg et al. [31]
TAF/TIM 201 3 months ITT Morning Hollo´ et al. [30]
TAF/TIM 283 3 months ITT Morning Pfeiffer et al. [20]
IOP intraocular pressure, ITT intention-to-treat, PP per-protocol, TAF/TIM ﬁxed-dose combination of 0.0015% taﬂuprost
and 0.5% timolol
a The endpoint calculated as a combined reduction in IOP over all time points during the 12-month or 6-week period
b Continuation of study by Brandt et al. [18] (same patients)
c In PP: 256 patients treated with preservative-free Ganfort and 260 patients with preserved Ganfort. By chance same
baseline IOP
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Fig. 1 (10 studies). The lowest and highest
mean baseline IOPs were seen in studies
conducted with DuoTrav: Hughes et al. [29]
and Schuman et al. [15] reported a mean of
around 24 mmHg and Barnebey et al. [16] a
mean of around 29 mmHg. Interestingly, the
reduction in mean IOP was smallest with the
first two studies (around 8 mmHg) and largest
with the third study (around 10 mmHg). In
other words, the mean IOP at baseline seemed
to predominantly explain the magnitude of
IOP reduction. In essence, our regression
Table 2 Incidence of conjunctival/ocular hyperemia and ocular irritation (burning, stinging, itching, foreign body











Xalacom 262 3 months BAC (0.02%) 3.1 2.3 Diestelhorst and
Larsson [39]
Xalacom 200 12 months BAC (0.02%) 2.5 9.0 Topouzis et al. [40]
Xalacom 129 3 months BAC (0.02%) 8.5 8.5 Higginbotham et al. [32]
Xalacom 170 3 months BAC (0.02%) 1.8 N/ac Palmberg et al. [41]
DuoTrav 161 3 months BAC (0.015%) 12.4 11.8 Hughes et al. [29]
DuoTrav 161 3 months BAC (0.015%) 14.3 23.6 Schuman et al. [15]
DuoTrav 85 3 months BAC (0.015%) 14.1 14.1 Barneyby et al. [16]
DuoTrav 207 12 months BAC (0.015%) 15.0 14.4 Topouzis et al. [40]











Kitasawa et al. [43]
Ganfort 176 3 weeks BAC (0.005%) 19.3 18.8 Hommer et al. [17]
Ganfort 533 3 months BAC (0.005%) 22.7 20.5 Brandt et al. [18]











Goldberg et al. [31]
TAF/TIM 201 6 months Preservative free 8.0 7.0 Hollo´ et al. [30]
TAF/TIM 283 6 months Preservative free 6.4 12.7 Pfeiffer et al. [20]
If information available in publication, percentages calculated from number of patients with individual adverse events,
otherwise by summing incidences
BAC benzalkonium chloride, IOP intraocular pressure, ITT intention-to-treat, PP per-protocol, TAF/TIM ﬁxed-dose
combination of 0.0015% taﬂuprost and 0.5% timolol
a Polyquad used at 0.001%
b Continuation of study by Brandt et al. [18] (same patients)
c Not possible to assess due to incomplete data in publication
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analysis confirmed this finding: there was an
outstanding linear relationship between the
mean baseline IOP and the treatment-induced
mean reduction in IOP across the 10 studies
with fixed-combination products. On the
grounds of the adjusted coefficient of
determination from the regression, 96% of
the variation in the mean IOP reduction was
solely explained by the variation in the mean
baseline IOP. The regression-based estimates of
IOP reduction were also well in line with the
published ones: for example, a mean reduction
of 8 mmHg (32%) was predicted for a mean
baseline IOP of 24 mmHg and a mean
reduction of 10 mmHg (36%) for a mean
baseline IOP of 29 mmHg. Naturally,
heterogeneity was increased, when the studies
with variable lengths and endpoints were
included in the analyses (16 studies);
nevertheless, this supplemental regression
analysis provided sound evidence on the
robustness of our primary results (Fig. 2).
A combined analysis of the two phase III
clinical trials with TAF/TIM [20, 30]
demonstrated a similar linear relationship
between the baseline IOP and magnitude of
IOP reduction (Fig. 3). It is worth noticing that
TAF/TIM had excellent IOP-reducing efficacy
beyond the above-mentioned range of baseline
IOPs: mean IOP reductions of up to 40%
Fig. 1 A scatter plot of the baseline mean IOP versus
reduction in mean IOP at 3 months based on the results of
double-masked, randomized studies of the ﬁxed-combination
products. Results are shown from studies in which washout
period from prior glaucoma medication was applied to have
corresponding untreated baseline IOP values and the mean
reduction at 3 months was available. Regression equation:
reduction in IOP = 5.306–0.545 9 (Baseline IOP). Slope
P value \0.0001, adjusted R2 0.957. IOP intraocular
pressure, TAF/TIM ﬁxed-dose combination of 0.0015%
taﬂuprost and 0.5% timolol
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([13 mmHg) were registered if the mean
baseline IOP was 31 mmHg or higher.
Side Effects
The most pronounced differences among the
combination products appear to be in the
incidence of side effects and tolerability
(Table 2). Conjunctival/ocular hyperemia
occurred at the highest occurrence with
Ganfort: around 20–25% of the patients
consistently exhibited hyperemia. Surprisingly,
there was no difference in this respect between
the preserved [benzalkonium chloride (BAC)]
and preservative-free formulations indicating
that the hyperemia is likely caused by an
inherent property of bimatoprost itself.
Corresponding figures for the other three
products were: around 13% (DuoTrav
preserved with BAC/polyquad), 7% (TAF/TIM),
and 4% (Xalacom preserved with BAC). It is
worth noticing that the results for the different
products were consistent across the individual
trials, for example, in the six DuoTrav trials
hyperemia occurred in 11–15% of the patients.
Ocular irritation was also most common in
patients treated with Ganfort and occurred in
most studies at an occurrence of 9–24%. The
corresponding figures for DuoTrav were
around 12–24% and for Xalacom around
Fig. 2 A scatter plot of the mean baseline IOP versus
reduction in mean IOP based on the results of double-
masked, randomized studies of the ﬁxed-combination
products. Results are shown from studies in which washout
period from prior glaucoma medication was applied to have
corresponding untreated baseline IOP. In addition to
studies in Fig. 1, studies with results from endpoints other
than 3 months are also included. Regression equation:
reduction in IOP = 5.559-0.557 9 (Baseline IOP). Slope
P value \0.0001, adjusted R2 0.874. IOP intraocular
pressure, TAF/TIM ﬁxed-dose combination of 0.0015%
taﬂuprost and 0.5% timolol
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2–9%. Ocular irritation during TAF/TIM
treatment occurred in about 7–13% of the
patients. Furthermore, adverse events in the
cornea occurred in most trials at low
frequencies; at the most in 3–4% of patients in
Ganfort and Xalacom trials [18, 19, 31, 32].
DISCUSSION
The double-masked, controlled phase III clinical
trials with the fixed prostaglandin–timolol
combination products—Xalacom, DuoTrav,
Ganfort, and TAF/TIM—were the basis of the
current review. The mechanism of IOP
reduction is similar for all of these products;
the reduction of aqueous humor production
induced by timolol, and the enhancement of
aqueous humor outflow via FP prostanoid
receptor activation induced by the
prostaglandin component. Based on the results
of our review, it is obvious that the capacity to
reduce IOP in patients with open-angle
glaucoma or ocular hypertension with the
products is approximately 32–36% from the
Fig. 3 IOP reduction at 3 months in patients treated with
TAF/TIM (ITT dataset). The graph is based on a
combined analysis of two phase III clinical trials (Hollo´
et al. [30] and Pfeiffer et al. [20]) for which the patient
population was stratiﬁed by daytime baseline IOP (mean of
3 or 4 measurements, n for each category in parenthesis for
every bar). It is evident that there is a direct relationship
between the baseline IOP and the IOP reduction. In
patients with mean baseline IOP of at least 31 mmHg the
mean reductions in IOP of 40% ([13 mmHg) were
achieved with TAF/TIM. A regression line from Fig. 1 was
included to further depict that TAF/TIM is competitive in
reducing IOP with regard to all other ﬁxed prostaglandin–
timolol combination products. IOP intraocular pressure,
ITT intention-to-treat, TAF/TIM ﬁxed-dose combination
of 0.0015% taﬂuprost and 0.5% timolol
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mean baseline pressures of around
24–29 mmHg. The regression analyses also
suggest that the four fixed-combination
products can be regarded as equally
efficacious, as the study-wise variations in the
magnitude of IOP reductions were explicitly
explained by the corresponding variations in
the baseline IOPs. Undoubtedly, our approach
to concentrate on double-masked, controlled
phase III trials with a parallel group design and
proper washout period reduced bias, but at the
same time it also diminished the spectrum of
available studies and data.
In a combined analysis of the two TAF/TIM
phase III studies [20, 30], an analogous linear
relationship between the baseline IOP and level
of IOP reduction was seen, and IOP decreases of
up to 40% and beyond were achieved when the
baseline IOP was 31 mmHg or higher. Such
pressure reductions would seem to be very
beneficial in the treatment of glaucoma with
high IOP. Moreover, the results of Pfeiffer et al.
[20] suggest that the superiority of TAF/TIM
over the underlying monotherapies—0.0015%
tafluprost once daily and 0.5% timolol twice
daily—was more pronounced in patients with a
high baseline IOP. Taken together, these results
indicate that baseline IOP has a distinct role in
the interpretation of study results and, clearly,
needs to be taken into account when choosing
the correct treatment option.
The most evident differences among the
combination products appear to be in the
incidence of side effects and tolerability; in
general, TAF/TIM and Xalacom seem to be
associated with fewer side effects. The safety
profile of timolol is well documented and does
not differentiate the combination products [11,
24]. All prostaglandin analogs are rather
selective FP prostanoid receptor agonists—also
bimatoprost after amide hydrolysis. However,
some subtle differences exist, which may
explain the differences. Below, we will delve
into these and also discuss the role of
preservatives.
Xalacom contains a very high
concentration of BAC (0.02%) and yet causes
conjunctival hyperemia on average in only
about 3% of the patients (Table 2), while
preservative-free Ganfort was recently shown
to cause hyperemia in about 21% of the patients
and the BAC-preserved Ganfort in about 20%
of the patients [31]. Therefore, it seems likely
that hyperemia is caused mainly by the
prostaglandin analog itself—as timolol is well
known to induce no or minimal hyperemia (or
irritation) in the eye, or may even help reducing
hyperemia induced by the other component of
the fixed combinations [24]. FP receptor-
mediated vasodilation is complex, and may
involve the release of secondary mediators
[33]. The concentration of the prostaglandin/
prostamide component in DuoTrav, Ganfort,
and TAF/TIM is high in relation to the EC50
value of the drugs, which may result in
overstimulation of the FP receptor on the
surface structures of the eye and cause more
frequent hyperemia compared to Xalacom,
which contains a less potent FP receptor
agonist latanoprost [1, 34]. TAF/TIM, on the
other hand, stimulates EP3 receptors [8, 9],
which can be expected to cause
vasoconstriction [7] and thereby counteract
part of the vasodilation caused by the FP
receptor stimulation. This could explain why
the hyperemia caused by TAF/TIM appears to be
less frequent and less severe than that of
Ganfort and DuoTrav.
Stimulation of the FP prostanoid receptor
does not seem to be associated with
nociception/irritation in the eye [1]. Therefore,
it is likely that co-stimulation of some other
receptor is of importance. Ganfort caused most
frequently ocular irritation (9–24%) and,
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indeed, bimatoprost-free acid (17-phenyl-
18,19,20-trinor-PGF2a) has significant
stimulatory effect on the EP1 prostanoid
receptor, which seems to be associated with
irritation in the eye [1, 34]. The preservative
(BAC in Xalacom and BAC/polyquad in
DuoTrav) can also be a plausible
explanation—or at least a contributing
factor—for the irritation: DuoTrav caused
irritation in 12–24% of the patients and
Xalacom in 2–9% of the patients, even
though travoprost-free acid (15R-fluprostenol)
is a more selective FP prostanoid receptor
agonist than latanoprost. TAF/TIM, in turn,
seemed to exert relatively little ocular
irritation, which could be due to the fact that
the eye drops are preservative free. On the other
hand, taking into account the relatively short
period of exposure, it is as likely that the
improved tolerability profile of TAF/TIM is due
to the active ingredient. Nevertheless, the
absence of preservative will certainly improve
the long-term tolerability of TAF/TIM.
Obviously, it is crucial to take into account
the length of the treatment when trying to
rationalize the reasons for the differences in the
incidence of side effects among the four fixed-
combination products (Table 2). The shortest of
the trials has lasted only 3 weeks (with
Ganfort) and the longest 12 months (with
Xalacom, DuoTrav, and Ganfort). The
importance of the length of the treatment is
illustrated by the studies of Brandt et al. [18]
and Lewis et al. [19] in which the same cohort of
patients continued treatment with Ganfort
from 3 to 12 months: A moderate increase was
seen both in hyperemia (from 22.7% at
3 months to 25.7% at 12 months) and
irritation (from 20.5% at 3 months to 23.8% at
12 months). Accordingly, a notable decline in
the IOP-reducing efficacy was seen from 3 to
12 months (Fig. 2). Hence, to avoid the
imminent bias, our primary regression analysis
was conducted on 3-month results. Moreover,
most of the trials included in the analysis of
safety had a duration of treatment up to
3–6 months (Table 2; 10 out of 16 studies);
therefore, the error imposed by the variation
in treatment length should not be significant
for the overall interpretation of the side effect
results either.
It should also be noted that subsequent to
the phase III studies a number of complete 24-h
crossover comparison studies have been
published with Xalacom, DuoTrav, and
Ganfort (e.g., [35–38]). These studies could
not be included in the current analysis; but
their clinical relevance is emphasized, as they
highlight the true overall efficacy of the
products and have revealed a convincing
separation between the products and
prostaglandin constituents. Such studies have
not yet been conducted with TAF/TIM
combination, but could be of future research
interest.
CONCLUSION
In conclusion, a review of the double-masked,
controlled, phase III clinical trials with the
fixed-combination products of prostaglandin
and timolol revealed that the products yielded
a similar reduction in IOP of approximately
32–36% from an untreated baseline IOP of
around 24–29 mmHg. A further look on TAF/
TIM studies indicated that IOP reductions of up
to 40% and beyond could be achieved for
untreated baseline pressures of 31 mmHg or
higher. Least side effects occurred during
treatment with TAF/TIM and Xalacom. Of
these two, only TAF/TIM is preservative free.
Although preservatives may induce ocular
surface problems, preservative-free Ganfort
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did not cause less hyperemia or irritation than
the preserved preparation indicating that these
side effects are associated with an inherent
property of bimatoprost.
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